Evidence map›Paper›PMID 30772373›Full record

ReviewMolecular and cellular endocrinology2019

Relaxin and fibrosis: Emerging targets, challenges, and future directions.

Anthony J Kanai, Elisa M Konieczko, Robert G Bennett, Chrishan S Samuel, Simon G Royce

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular and cellular endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Genomics of Human Fibrotic Diseases: Disordered Wound Healing Response.International journal of molecular sciences · 2020
    Review
  11. Article
  12. Article
  13. Review
  14. Serelaxin and the ATACS pharmacology & translational science · 2020
    Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Anthony J KanaiDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: ajk5@pitt.edu.
Elisa M KonieczkoBiology Department, Morosky College of Health Professions and Sciences, Gannon University, Erie, PA, USA. Electronic address: konieczk001@gannon.edu.
Robert G BennettResearch Service, VA Nebraska-Western Iowa Health Care System, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA; Research Service, VA Nebraska-Western Iowa Health Care System, Department of Biochemistry & Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address: rgbennet@unmc.edu.
Chrishan S SamuelCardiovascular Disease Theme, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, VIC, Australia. Electronic address: chrishan.samuel@monash.edu.
Simon G RoyceCardiovascular Disease Theme, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, VIC, Australia; Central Clinical School, Monash University, Prahran, VIC, Australia. Electronic address: simon.royce@monash.edu.
Discovery Institute · USGannon University · USNebraska Medical Center · USUniversity of Pittsburgh · US

Funding

Urothelium in Detrusor OveractivityP01DK093424 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DEGROAT, WILLIAM C · 2013 to 2017
$7.9M
PDE5 Inhibition of Afferents and Interstitial Cells in Overactive Mouse BladdersR01DK098361 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BIRDER, LORI A, KANAI, ANTHONY JOHN · 2014 to 2024
$5.7M
Roles of Nitric Oxide and Superoxide in CystitisR01DK071085 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KANAI, ANTHONY JOHN · 2005 to 2017
$3.3M
Relaxin and PPAR gamma Activation for Liver Disease TreatmentI01BX000849 · VA · OMAHA VA MEDICAL CENTER · PI BENNETT, ROBERT G · 2011 to 2019
–
BLRD VA I01 BX000849NIDDK NIH HHS P01 DK093424NIDDK NIH HHS R01 DK071085NIDDK NIH HHS R01 DK098361
6 · The paper itself

Abstract

The peptide hormone relaxin is well-known for its anti-fibrotic actions in several organs, particularly from numerous studies conducted in animals. Acting through its cognate G protein-coupled receptor, relaxin family peptide receptor 1 (RXFP1), serelaxin (recombinant human relaxin) has been shown to consistently inhibit the excessive extracellular matrix production (fibrosis) that results from the aberrant wound-healing response to tissue injury and/or chronic inflammation, and at multiple levels. Furthermore, it can reduce established scarring by promoting the degradation of aberrant extracellular matrix components. Following on from the review that describes the mechanisms and signaling pathways associated with the extracellular matrix remodeling effects of serelaxin (Ng et al., 2019), this review focuses on newly identified tissue targets of serelaxin therapy in fibrosis, and the limitations associated with (se)relaxin research.

Indexed as

AnimalsCollagenElectromyographyFibrosisHumansRelaxinCollagenRelaxinChallenges and future directionsEmerging targetsExtracellular matrixFibrosisRelaxinRXFP1

Identifiers

PMID30772373
PMCPMC6475456
OpenAlexW2911631322

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.